Trader bets on major rally in coming months.
April 17th $80 call options on Gilead Sciences (GILD) saw a 38-fold rise in trading, going from 805 open contacts to over 30,300 trade hands.
The bet, expiring in just 68 days, is that shares will move about $12 higher from their price of $68, or about 17.6 percent.
- Do You Own Any of These Toxic Stocks?
Investing legend Louis Navellier just released a list of 250 toxic stocks to SELL NOW.
Some will drop even further from here.
Other are “zombie” stocks that will take years to recover.
Some won’t survive. 10 minutes is all it takes to give your portfolio a complete checkup and sleep easier knowing you don’t own any of these ticking time bombs.
The total returns on shares will have to clear 20 percent by expiration, given that the buyer of the options paid $1.30 for the stake.
Gilead Sciences, a biotech company working on a variety of drugs related to the treatment of sexually-transmitted diseases, has attracted investor interest lately as one of its HIV drugs seems to be effective against the coronavirus. Shares of the company are down 2 percent in the past year.
Action to take: We like the values in the biotech space, along with insiders. And if a coronavirus treatment moves the company higher, it will be a standout investment in a sector that’s otherwise been a lackluster place to invest.
Trading at 11 times forward earnings and yielding just under 4 percent, shares look attractive here. We’re also upping our maximum buy price to $70 per share, as the company is far more valuable with a coronavirus treatment.
Speculators may want to get into the April call trade, at the very least as a hedge against further coronavirus shocks to the market.